Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution

This prospective study from Bologna, Italy, involving 202 patients with cutaneous melanoma undergoing immunotherapy, found that 37.5% developed skin adverse events, primarily due to ipilimumab, nivolumab, and pembrolizumab. Common reactions included erythematous rash, vitiligo, and alopecia, with most being mild to moderate. Severe cases were rare but significant, with one instance leading to permanent pembrolizumab discontinuation. The study highlights the importance of dermatological assessments, as skin irAEs were linked to improved overall survival, suggesting they may indicate a positive treatment response. However, the study's conclusions are limited by its single-center scope and sample size.